The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Tetrabenazine in the treatment of hyperkinetic movement disorders
Abstract
Tetrabenazine, a dopamine-depleting agent first synthesized half a century ago, was initially developed for the treatment of schizophrenia. Although psychotic disorders have since been treated more successfully with other neuroleptic medications, many studies have shown this drug to be effective in the treatment of hyperkinetic movement disorders (hyperkinesias). Hyperkinesias are neurologic disorders characterized by abnormal involuntary movements such as chorea associated with Huntington's disease, tics in Tourette's syndrome and stereotypies in tardive dyskinesia. Recently, clinical trials investigating tetrabenazine for the treatment of chorea associated with Huntington's disease found the drug to be safe and efficacious, making approval by the US Food and Drug Administration for this indication a distinct possibility.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Cited by
Jankovic, J. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70574-9 · Cited by 332
Self-citationHemidystonia: a report of 22 patients and a review of the literature.
Pettigrew, L. C., & Jankovic, J. (1985) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.48.7.650 · Cited by 284
Self-citationTreatment of hyperkinetic movement disorders
Jankovic, J. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70183-8 · Cited by 252
Self-citationVesicular monoamine transporter 2: Role as a novel target for drug development
Zheng, G., Dwoskin, L. P., & Crooks, P. A. (2006) · The AAPS Journal · doi:10.1208/aapsj080478 · Cited by 125
Fasano, A., & Bentivoglio, A. R. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903386292 · Cited by 51
Metadata
- Authors
- Kenney, C., & Jankovic, J.
- Venue
- Expert Review of Neurotherapeutics
- Publisher
- Informa UK Limited
- Published
- 2006-01
- Volume
- 6
- Issue
- 1
- Pages
- 7-17
- ISSN
- 1473-7175 (ISSN-L)
- 1744-8360
- OpenAlex
- W2063242260
- Cited by
- 158
- References
- 1
- FWCI
- 10.46
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.